Form 4: NKGen Biotech Grants Stock Options to Michael Klowden

NKGen Biotech granted Michael Klowden a total of 800,000 stock options on December 6, 2024, under the company's 2023 Equity Incentive Plan.

Summary

• On December 6, 2024, Michael Klowden received two stock option grants from NKGen Biotech.
• The first grant was for 300,000 options with an exercise price of $1.62 per share.
• 40% of these options vested immediately, and the remaining options will vest in 20 equal monthly installments starting January 6, 2025, and ending August 6, 2026.
• The second grant was for 500,000 options with an exercise price of $0.438 per share.
• These options will vest in 36 equal monthly installments starting January 6, 2025, and ending December 6, 2027.
• Both grants are subject to Klowden's continued service with NKGen Biotech.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally positive for employee retention and alignment of interests. There are no negative implications.

Positives

• The stock option grants serve as an incentive for Michael Klowden to remain with NKGen Biotech.
• The vesting schedule aligns Klowden's interests with the long-term performance of the company.

Risks

• The value of the options is dependent on the future performance of NKGen Biotech's stock price.
• If Klowden leaves the company before the options fully vest, he may forfeit some or all of the unvested options.

Future Outlook

The vesting of the options is contingent on Michael Klowden's continued service with the company, suggesting a focus on retaining key personnel.

Industry Context

Stock options are a common form of compensation in the biotech industry, used to attract and retain talent and align employee interests with company performance.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry, often used to incentivize key employees.
• The vesting schedules described are typical, with a mix of immediate and time-based vesting to encourage long-term commitment.
• The exercise prices are likely based on the company's stock valuation at the time of the grant, which is a common practice.

Stakeholder Impact

• Shareholders may view the stock option grants as a positive sign of management's commitment to the company.
• Employees may be motivated by the potential for equity ownership.

Key Dates

Keywords

stock options, equity incentive plan, vesting, Michael Klowden, NKGen Biotech, compensation